Boston Scientific Comprehensive Income 2010-2025 | BSX
Boston Scientific comprehensive income from 2010 to 2025. Comprehensive income can be defined as the change in net assets of a business enterprise during a period from transactions and other events and circumstances from nonowner sources. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners.
- Boston Scientific comprehensive income for the quarter ending March 31, 2025 was $275M, a 461.22% increase year-over-year.
- Boston Scientific comprehensive income for 2024 was $0.275B, a 461.22% increase from 2023.
- Boston Scientific comprehensive income for 2023 was $0.049B, a 81.78% decline from 2022.
- Boston Scientific comprehensive income for 2022 was $0.269B, a 2.28% increase from 2021.
| Boston Scientific Annual Comprehensive Income (Millions of US $) |
|
|---|---|
| 2024 | $275 |
| 2023 | $49 |
| 2022 | $269 |
| 2021 | $263 |
| 2020 | $207 |
| 2019 | $270 |
| 2018 | $33 |
| 2017 | $-59 |
| 2016 | $1 |
| 2015 | $88 |
| 2014 | $144 |
| 2013 | $106 |
| 2012 | $-33 |
| 2011 | $-138 |
| 2010 | $-129 |
| 2009 | $-43 |
| Boston Scientific Quarterly Comprehensive Income (Millions of US $) |
|
|---|---|
| 2024-12-31 | $275 |
| 2024-09-30 | $-128 |
| 2024-06-30 | $164 |
| 2024-03-31 | $132 |
| 2023-12-31 | $49 |
| 2023-09-30 | $231 |
| 2023-06-30 | $208 |
| 2023-03-31 | $178 |
| 2022-12-31 | $269 |
| 2022-09-30 | $532 |
| 2022-06-30 | $433 |
| 2022-03-31 | $222 |
| 2021-12-31 | $263 |
| 2021-09-30 | $238 |
| 2021-06-30 | $237 |
| 2021-03-31 | $254 |
| 2020-12-31 | $207 |
| 2020-09-30 | $151 |
| 2020-06-30 | $131 |
| 2020-03-31 | $168 |
| 2019-12-31 | $270 |
| 2019-09-30 | $138 |
| 2019-06-30 | $78 |
| 2019-03-31 | $87 |
| 2018-12-31 | $33 |
| 2018-09-30 | $25 |
| 2018-06-30 | $-16 |
| 2018-03-31 | $-128 |
| 2017-12-31 | $-59 |
| 2017-09-30 | $-51 |
| 2017-06-30 | $-53 |
| 2017-03-31 | $-46 |
| 2016-12-31 | $1 |
| 2016-09-30 | $-99 |
| 2016-06-30 | $-70 |
| 2016-03-31 | $35 |
| 2015-12-31 | $88 |
| 2015-09-30 | $81 |
| 2015-06-30 | $104 |
| 2015-03-31 | $142 |
| 2014-12-31 | $144 |
| 2014-09-30 | $110 |
| 2014-06-30 | $42 |
| 2014-03-31 | $72 |
| 2013-12-31 | $106 |
| 2013-09-30 | $56 |
| 2013-06-30 | $82 |
| 2013-03-31 | $45 |
| 2012-12-31 | $-33 |
| 2012-09-30 | $-112 |
| 2012-06-30 | $-87 |
| 2012-03-31 | $-79 |
| 2011-12-31 | $-138 |
| 2011-09-30 | $-132 |
| 2011-06-30 | $-123 |
| 2011-03-31 | $-119 |
| 2010-12-31 | $-129 |
| 2010-09-30 | |
| 2010-06-30 | |
| 2010-03-31 | $-18 |
| 2009-12-31 | $-43 |
| 2009-09-30 | |
| 2009-06-30 | |
| 2009-03-31 | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | MED PRODUCTS | $152.625B | $16.747B |
| Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments - Cardiovascular, Rhythm and Neuro and MedSurg. While Cardiovascular includes Interventional Cardiology and Peripheral Interventions, Rhythm and Neuro comprises Cardiac Rhythm Management, Electrophysiology and Neuromodulation. The MedSurg group comprises 2 sub segments, viz. Endoscopy, Urology and Pelvic Health. Boston Scientific markets a broad portfolio of internally-developed and self-manufactured drug eluting stents including the Promus PREMIER, Promus Element and Promus Element Plus everolimus-eluting stents. Within the CRM segment, the company deals with implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities. | |||